Tilsotolimod exploits the TLR9 pathway to promote antigen presentation and Type 1 IFN signaling in solid tumors: A Multicenter International Phase I/II trial (ILLUMINATE-101).

Babiker H, Borazanci E, Subbiah V, et al. "Tilsotolimod exploits the TLR9 pathway to promote antigen presentation and Type 1 IFN signaling in solid tumors: A Multicenter International Phase I/II trial (ILLUMINATE-101)." Clin Cancer Res. 2022.